Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
Background/Aims: Increased prevalence of nonalcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD) has been reported. However, the effects of NAFLD on the outcome of IBD remains unclear. We investigated whether the presence of NAFLD could influence the outcomes of patients with IBD.
Methods: We recruited 3,356 eligible patients with IBD into our study between November 2005 and November 2020. Hepatic steatosis and fibrosis were diagnosed using hepatic steatosis index of ≥30 and fibrosis-4 of ≥1.45, respectively. The primary outcome was clinical relapse, defined based on the following: IBD-related admission, surgery, or first use of corticosteroids, immunomodulators, or biologic agents for IBD.
Results: The prevalence of NAFLD in patients with IBD was 16.7%. Patients with hepatic steatosis and advanced fibrosis were older, had a higher body mass index, and were more likely to have diabetes (all p<0.05).
Conclusions: Hepatic steatosis was independently associated with increased risks of clinical relapse in patients with ulcerative colitis and Crohn's disease, whereas fibrotic burden in the liver was not. Future studies should investigate whether assessment and therapeutic intervention for NAFLD will improve the clinical outcomes of patients with IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Gut and liver - 18(2024), 2 vom: 15. März, Seite 294-304 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hyun, Hye Kyung [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hepatic steatosis |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 16.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5009/gnl220409 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357059719 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357059719 | ||
| 003 | DE-627 | ||
| 005 | 20240316232510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5009/gnl220409 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM357059719 | ||
| 035 | |a (NLM)37203442 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hyun, Hye Kyung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background/Aims: Increased prevalence of nonalcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD) has been reported. However, the effects of NAFLD on the outcome of IBD remains unclear. We investigated whether the presence of NAFLD could influence the outcomes of patients with IBD | ||
| 520 | |a Methods: We recruited 3,356 eligible patients with IBD into our study between November 2005 and November 2020. Hepatic steatosis and fibrosis were diagnosed using hepatic steatosis index of ≥30 and fibrosis-4 of ≥1.45, respectively. The primary outcome was clinical relapse, defined based on the following: IBD-related admission, surgery, or first use of corticosteroids, immunomodulators, or biologic agents for IBD | ||
| 520 | |a Results: The prevalence of NAFLD in patients with IBD was 16.7%. Patients with hepatic steatosis and advanced fibrosis were older, had a higher body mass index, and were more likely to have diabetes (all p<0.05) | ||
| 520 | |a Conclusions: Hepatic steatosis was independently associated with increased risks of clinical relapse in patients with ulcerative colitis and Crohn's disease, whereas fibrotic burden in the liver was not. Future studies should investigate whether assessment and therapeutic intervention for NAFLD will improve the clinical outcomes of patients with IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hepatic steatosis | |
| 650 | 4 | |a Inflammatory bowel diseases | |
| 650 | 4 | |a Liver fibrosis | |
| 650 | 4 | |a Non-alcoholic fatty liver disease | |
| 650 | 4 | |a Outcome | |
| 700 | 1 | |a Lee, Hye Won |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jihye |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Soo Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jae Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Tae Il |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jae Seung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Beom Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jun Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Do Young |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Sang Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seung Up |e verfasserin |4 aut | |
| 700 | 1 | |a Cheon, Jae Hee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gut and liver |d 2007 |g 18(2024), 2 vom: 15. März, Seite 294-304 |w (DE-627)NLM197725406 |x 2005-1212 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:2 |g day:15 |g month:03 |g pages:294-304 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5009/gnl220409 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 2 |b 15 |c 03 |h 294-304 | ||